[go: up one dir, main page]

MX2010008688A - Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. - Google Patents

Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.

Info

Publication number
MX2010008688A
MX2010008688A MX2010008688A MX2010008688A MX2010008688A MX 2010008688 A MX2010008688 A MX 2010008688A MX 2010008688 A MX2010008688 A MX 2010008688A MX 2010008688 A MX2010008688 A MX 2010008688A MX 2010008688 A MX2010008688 A MX 2010008688A
Authority
MX
Mexico
Prior art keywords
engineered anti
tslpr antibodies
tslpr
antibodies
engineered
Prior art date
Application number
MX2010008688A
Other languages
English (en)
Inventor
Leonard G Presta
Waal Malefyt Rene De
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010008688A publication Critical patent/MX2010008688A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a compuestos de unión que específicamente se unen al TSLPR humano, así como también a usos de los mismos, por ejemplo, en el tratamiento de trastornos inflamatorios.
MX2010008688A 2008-02-07 2009-02-06 Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. MX2010008688A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2683308P 2008-02-07 2008-02-07
US4203008P 2008-04-03 2008-04-03
PCT/US2009/033383 WO2009100324A1 (en) 2008-02-07 2009-02-06 Engineered anti-tslpr antibodies

Publications (1)

Publication Number Publication Date
MX2010008688A true MX2010008688A (es) 2010-08-30

Family

ID=40622088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008688A MX2010008688A (es) 2008-02-07 2009-02-06 Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.

Country Status (8)

Country Link
US (1) US8475793B2 (es)
EP (1) EP2250199B1 (es)
JP (2) JP2011511638A (es)
CN (1) CN101986784A (es)
AR (1) AR070346A1 (es)
CA (1) CA2713935C (es)
MX (1) MX2010008688A (es)
WO (1) WO2009100324A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170957A1 (en) 2007-06-20 2010-04-07 Irm, Llc Methods and compositions for treating allergic diseases
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8598119B2 (en) 2008-05-27 2013-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
WO2012054438A1 (en) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
LT3031913T (lt) * 2013-08-09 2019-05-27 Astellas Pharma Inc. Naujas antikūnas, atpažįstantis žmogaus tslp receptorių
US9790506B2 (en) 2013-10-02 2017-10-17 The Regents Of The University Of California Diagnostic and screening methods for atopic dermatitis
PL3076967T3 (pl) 2013-12-03 2021-12-20 Intra-Cellular Therapies, Inc. Metody leczenia objawów rezydualnych schizofrenii
RU2701346C1 (ru) * 2013-12-06 2019-09-25 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
CU24533B1 (es) 2015-09-09 2021-07-02 Novartis Ag Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
TN2018000076A1 (en) 2015-09-09 2019-07-08 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
TWI836745B (zh) 2015-12-18 2024-03-21 美商上游生物公司 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物
HUE053737T2 (hu) 2016-01-26 2021-07-28 Intra Cellular Therapies Inc Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
WO2017146011A1 (ja) * 2016-02-22 2017-08-31 国立大学法人 千葉大学 アレルギー性鼻炎の診断用バイオマーカー
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
KR20240141212A (ko) 2017-03-24 2024-09-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 조성물 및 방법
AU2019205489A1 (en) * 2018-01-05 2020-06-25 Amgen, Inc. Anti-MCT1 antibodies and uses thereof
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
EP3843729A4 (en) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
CN118873536A (zh) 2018-08-31 2024-11-01 细胞内治疗公司 新方法
WO2020047407A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
JP2022519118A (ja) * 2019-02-01 2022-03-18 ノヴァロック バイオセラピューティクス， リミテッド 抗クローディン１８抗体及びそれらの使用の方法
JP2022525703A (ja) * 2019-03-20 2022-05-18 ジャベリン・オンコロジー・インコーポレイテッド 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法
US20220298255A1 (en) * 2019-05-31 2022-09-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
WO2023028612A2 (en) 2021-08-27 2023-03-02 Board Of Regents, The University Of Texas System Anti-tslpr (crlf2) antibodies
WO2023155132A1 (zh) * 2022-02-18 2023-08-24 绍兴守仁医疗健康科技有限公司 Rac1蛋白单克隆抗体及其制备方法与应用
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
JP2025538151A (ja) 2022-11-07 2025-11-26 アップストリーム バイオ インコーポレイテッド 抗ヒトｔｓｌｐ受容体抗体を含む医薬組成物及びその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317917T3 (es) 2000-06-28 2009-05-01 Amgen Inc. Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas.
CA2577631A1 (en) * 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
KR101383472B1 (ko) * 2006-01-13 2014-04-08 아이알엠 엘엘씨 알레르기 질병 치료를 위한 흉선 간질 림포포이에틴수용체에 대한 항체
EP2170957A1 (en) 2007-06-20 2010-04-07 Irm, Llc Methods and compositions for treating allergic diseases

Also Published As

Publication number Publication date
CA2713935A1 (en) 2009-08-13
EP2250199B1 (en) 2015-09-02
EP2250199A1 (en) 2010-11-17
JP2011511638A (ja) 2011-04-14
US20110020369A1 (en) 2011-01-27
JP2013223516A (ja) 2013-10-31
US8475793B2 (en) 2013-07-02
AR070346A1 (es) 2010-03-31
CA2713935C (en) 2016-11-01
WO2009100324A1 (en) 2009-08-13
CN101986784A (zh) 2011-03-16

Similar Documents

Publication Publication Date Title
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
PH12013500355A1 (en) Engineered anti-tslp antibody
MY162511A (en) Engineered anti-tslp antibody
PH12013500810B1 (en) Anti-il-23 antibodies
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
PH12014501108A1 (en) Anti-il-36r antibodies
WO2012109373A3 (en) Treatment of osteoarthritis and pain
TN2010000213A1 (en) Wise binding antibodies and epitopes
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
PH12012502523A1 (en) Dual variable domain immunoglobulins and uses thereof
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500815A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
MY163368A (en) Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
PH12013502205A1 (en) Antibodies to il-6 and their uses
NZ709353A (en) Antibodies that bind il-4 and/or il-13 and their uses
EP2373692A4 (en) IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
MY161679A (en) Polypeptides
PH12017500864A1 (en) Anti-notch1 antibodies

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status